Perioperative Propranolol in Patients With Post Traumatic Stress Disorder (PTSD)

Effect of Prophylactic, Perioperative Propranolol on Peri- and Postoperative Complications in Patients With Post Traumatic Stress Disorder

Understanding what treatments may facilitate perioperative care of Veterans with posttraumatic stress disorder (PTSD) is of great importance to the U.S. health care system.

Patients with PTSD are characterized by elevated central nervous system catecholamine concentrations and exaggerated and prolonged adrenergic responses to stress stimuli. At present, there are no data on the effects of perioperative beta blocker therapy in patients with PTSD, despite the rising significance of PTSD in Veteran populations.

This prospective, double-blind study proposes to randomize 150 Veterans with PTSD scheduled for orthopedic, thoracic or vascular surgery at the San Francisco VA Medical Center to either a 14-day course of propranolol or placebo. This study will then follow these Veterans for a one-year period to evaluate the effects of the intervention on Veterans' surgical outcomes.

The investigators hypothesize that patients with PTSD randomized to the propranolol group will demonstrate a reduced incidence of perioperative and postoperative morbidity and mortality.

Study Overview

Status

Terminated

Study Type

Interventional

Enrollment (Actual)

59

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • San Francisco, California, United States, 94121
        • San Francisco VA Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Subjects scheduled for any surgical procedure under general anesthesia or combined general-regional anesthesia, with the exception of open-heart or intracranial surgery. Regional anesthesia includes: 1) Epidural anesthesia, 2) Sub-arachnoid block (spinal), or 3)any regional nerve block
  2. Anticipated postoperative hospital admission (defined as at least one overnight hospital stay)

Exclusion Criteria:

Veterans will be excluded if:

  1. They are on beta blocker therapy at the time of the preoperative baseline assessment
  2. They report sensitivity or allergies to propranolol, or a history of PTSD exacerbation with prior propranolol therapy
  3. Veterans who fulfill the AHA/ACC level I recommendation criteria for perioperative beta blocker therapy (e.g., metoprolol, atenolol) and should not be randomized to placebo group
  4. Medical exclusions criteria: high grade heart block without pacemaker (all patients with 2nd and 3rd degree heart block), marked resting bradycardia (heart rate ≤ 55 beats per minute), blood pressure < 100 mmHg, uncompensated congested heart failure, severe hyperactive airway disease, and Raynaud's disease
  5. Pregnancy
  6. Current use of medication that may involve potentially dangerous interaction with propranolol
  7. Circumstances that, in the opinion of the principal investigator, would preclude participation in a study of this type (e.g. medical concerns or difficulty in long-term followup).
  8. Open-heart surgery and intracranial surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo Group

The placebo pill will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first placebo pill to be taken once daily by mouth.

On post operative days #1-13, patients will take one placebo pill (once daily by mouth).

This will complete the course of the placebo.

Experimental: Propranolol Hydrochloride

Propranolol will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first dose of the study drug (the PDR recommended starting dose of Propranolol XL- Extended Release). Patients will take one 60 mg pill on the morning of surgery.

On post operative day #1, patients will take one pill of receive propranolol XL 80 mg (once daily by mouth).

On post operative days #2-#9, patients will take one pill of propranolol XL 120 mg (once daily by mouth).

On post operative days #10-11, patients will take one pill of propranolol XL 80 mg (once daily by mouth).

On post operative days #12-13, patients will take one pill of propranolol XL 60 mg (once daily by mouth).

This will complete the course of propranolol.

Other Names:
  • Inderal
  • Inderal LA
  • Avlocardyl
  • Deralin
  • Dociton
  • Inderalici
  • InnoPran XL
  • Sumial
  • Anaprilinum
  • Avlocardyl Retard
  • Bedranol SR Sandoz

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ICU Length of Stay
Time Frame: Truncated at 30 days after admission to ICU
Measured using patient medical records
Truncated at 30 days after admission to ICU
Hospital Length of Stay
Time Frame: Truncated at 30 days after admission to ICU
Measured using patient medical records
Truncated at 30 days after admission to ICU
Postoperative Delirium
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 week
Measured using Confusion Assessment Method (CAM-CAM-ICU)
Participants will be followed for the duration of hospital stay, an expected average of 1 week
Postoperative Renal Dysfunction
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 week
Measured using Serum Creatinine laboratory values
Participants will be followed for the duration of hospital stay, an expected average of 1 week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Perioperative Complications
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 week
Measured using patient medical records
Participants will be followed for the duration of hospital stay, an expected average of 1 week
Pain Intensity
Time Frame: 12 months
Pain intensity was measured using a Numerical Rating Scale (NRS). The range of the NRS is 0 and 10, where zero represents no pain at all and 10 represents the worst pain ever possible.
12 months
Pain Unpleasantness
Time Frame: 12 months
Measured using the Numerical Rating Scale (NRS). The range of the NRS is 0 and 10, where zero represents no pain at all and 10 represents the worst pain ever possible.
12 months
Perioperative Opioids Use
Time Frame: Participants will be followed from preoperative baseline to 1 year postoperative
Measured using patient medical records.
Participants will be followed from preoperative baseline to 1 year postoperative
Required Mechanical Ventilation
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 week
Measured using patient medical records
Participants will be followed for the duration of hospital stay, an expected average of 1 week
Change in Posttraumatic Diagnostic Scale (PDS) PTSD Symptoms Severity Score
Time Frame: Baseline and 12 months
The Posttraumatic Diagnostic Scale (PDS) Scale includes a PTSD Symptoms Severity Score ranging from 0 to 51, with higher scores indicating more severe depression.
Baseline and 12 months
Change in Mental Component Summary (MCS) Scores From the Short Form-36 Questionnaire (SF-36)
Time Frame: Participants will be followed from preoperative baseline to 1 year postoperative
The Mental Component Summary (MCS) score is derived from the Short Form-36 Questionnaire (SF-36), a validated measure of health-related quality of life. Scores range from 0 to 100, with higher scores indicating better mental health and lower scores indicating worse mental health.
Participants will be followed from preoperative baseline to 1 year postoperative
Change in Physical Component Summary (PCS) Scores From the Short Form-36 Questionnaire (SF-36)
Time Frame: Participants will be followed from preoperative baseline to 1 year postoperative
The Physical Component Summary (PCS) score is derived from the Short Form-36 Questionnaire (SF-36), a validated measure of health-related quality of life. Scores range from 0 to 100, with higher scores indicating better physical health and lower scores indicating worse physical health.
Participants will be followed from preoperative baseline to 1 year postoperative
Change in Pittsburgh Sleep Quality Index (PSQI) Score
Time Frame: Participants will be followed from preoperative baseline to 1 year postoperative
The Pittsburgh Sleep Quality Index (PSQI) is a validated self-reported questionnaire assessing sleep quality. Total scores range from 0 to 21, with higher scores indicating worse sleep quality and lower scores indicating better sleep quality
Participants will be followed from preoperative baseline to 1 year postoperative
Change in Beck Depression Inventory (BDI) Score
Time Frame: Participants will be followed from preoperative baseline to 1 year postoperative
The Beck Depression Inventory (BDI) is a validated self-report measure of depressive symptoms. Total scores range from 0 to 63, with higher scores indicating more severe depressive symptoms (worse outcome) and lower scores indicating fewer or minimal symptoms (better outcome).
Participants will be followed from preoperative baseline to 1 year postoperative
Postoperative Neurocognitive Dysfunction Score
Time Frame: Participants will be followed from preoperative baseline to 1 year postoperative
The Mini-Mental State Examination (MMSE) is a widely used screening tool for cognitive function. Total scores range from 0 to 30, with higher scores indicating better cognitive function and lower scores indicating greater cognitive impairment.
Participants will be followed from preoperative baseline to 1 year postoperative
30-day, 3-month, and 1-year Mortality
Time Frame: Participants will be followed from preoperative baseline to 1 year postoperative
Measured using patient medical records
Participants will be followed from preoperative baseline to 1 year postoperative
Postoperative Complications
Time Frame: Participants will be followed to 1 year postoperative
Measured using patient medical records - Composite outcome measure that included, delirium, stroke, myocardial infarction, acute kidney injury, new atrial fibrilation, infection, or congestive heart failure between the surgery and 1-yr.
Participants will be followed to 1 year postoperative

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Marek Brzezinski, M.D., Ph.D., University of California, San Francisco

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2012

Primary Completion (Actual)

June 1, 2018

Study Completion (Actual)

June 1, 2019

Study Registration Dates

First Submitted

March 5, 2012

First Submitted That Met QC Criteria

March 13, 2012

First Posted (Estimated)

March 15, 2012

Study Record Updates

Last Update Posted (Actual)

July 2, 2026

Last Update Submitted That Met QC Criteria

June 8, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe